Burns - Pipeline Insight, 2024

Burns - Pipeline Insight, 2024

DelveInsight’s, “Burns - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Burns pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Burns Understanding

Burns: Overview

Burns are the most distressing forms of injury causing extensive pain and damage to the skin. They are considered as one of the leading causes of death worldwide. Everyday 30,000 people are affected with burns, which accounts to over 11 million people globally every year. Inadequate access to timely, safe and efficient care continues to be a major global health concern. Based on the extent and severity of the injury burns are mainly categorised into three types: First degree: affecting the superficial layer of the skin; Second degree: extending beyond the superficial layer affecting both, the epidermis and the dermis; and Third degree: extending beyond the dermis causing nerve damage. Management of burn wounds is carried out by five sequential steps; first aid, initial treatment, daily treatment, healing phase and nutrition. In second degree burns, as the injury extends beyond the epidermis they are more prone to wound infections, which requires careful monitoring in order to prevent serious complications. A number of advanced combination products with antimicrobial and wound healing properties are available for burn wound care which are much easier and efficient than the daily dressing changes. Researchers have also identified modified approaches to address the unmet medical needs in wound care.

""Burns - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Burns pipeline landscape is provided which includes the disease overview and Burns treatment guidelines. The assessment part of the report embraces, in depth Burns commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Burns collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Burns R&D. The therapies under development are focused on novel approaches to treat/improve Burns.

Burns Emerging Drugs Chapters

This segment of the Burns report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Burns Emerging Drugs

• NMT- cP12: NeoMatrix Therapeutics

NMT- cP12 is a novel, bioactive peptide for intravenous treatment of burns within 2 to 4 hours of injury. NMT- cP12 has the potential to limit burn injury progression, shorten healing time, and reduce scarring of deep or extensive burns in hospitalized patients. FDA has granted NMT-cP12 Orphan and Fast Track Designation for severe burns. NMT-cP12 is a novel Fibronectin (FN) derived, 14-mer peptide (P12) from the first FN type III repeat that promotes mesenchymal cell growth, proliferation and migration in vitro and acts synergistically with a variety of growth factors including platelet-derived growth factor-BB. FN has been shown to play a vital role in wound healing and is deficient in burn patients’ wounds and blood. P12 protects adult human dermal fibroblasts from cell death induced by oxidative and cytokine stress in vitro. In addition, blood vessel occlusion in burns is well-known and results in impaired oxygenation and ultimately tissue necrosis in the peri-burn tissue. NMT-cP12 has been demonstrated in animal models to vasodilate the microvasculature and to reduce blood vessel occlusion. Thereby, a single infusion of NMT-cP12 limits burn injury progression, speeds healing and reduces scarring in a porcine burn model.

Further product details are provided in the report……..

Burns: Therapeutic Assessment

This segment of the report provides insights about the different Burns drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Burns

There are approx. 12+ key companies which are developing the therapies for Burns. The companies which have their Burns drug candidates in the most advanced stage, i.e. phase I include, NeoMatrix Therapeutics.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Burns pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Burns: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Burns therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Burns drugs.

Burns Report Insights

• Burns Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Burns Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Burns drugs?
• How many Burns drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Burns?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Burns therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Burns and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• NeoMatrix Therapeutics
• Amniotics
• Alloksys Life Sciences
• Medline Industries
• Skingenix, Inc.
• Anterogen
• Noveome Biotherapeutics
• Phagelux Inc.
• Bioharmony Therapeutics
• Amarantus Bioscience

Key Products

• NMT- cP12
• Skin disorder specific amniotic mesenchymal stem cell therapy
• bRESCAP
• PluroGel
• MW-III
• ALLO-ASC-BI
• ST266
• Bacteriophage cocktail spray
• BH02
• PermaDerm